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Abstract The substantial economic impact of influenza
on society results primarily from lost work time and
reduced productivity of patients and caregivers and
increased use of medical resources. Additionally, since the
1980s, aging of the US population has meant rising influ-
enza-related morbidity and mortality. According to the
most current published data on this topic, in 2003 the total
economic burden of influenza epidemics in the USA across
all age groups was US$87.1 billion. As of February 2013,
overall vaccine effectiveness for the 2012/2013 season was
estimated to be 56 %. The Centers for Disease Control and
Prevention’s National Center for Immunization and
Respiratory Diseases has concluded that more effective
vaccines and vaccination strategies are needed. Moderate
efficacy of the influenza vaccine, continued questions
regarding the value of treatment with antivirals, and a
growing self-care movement have led to increased use of
over-the-counter (OTC) medicines, which play a vital role
in managing symptoms associated with mild to moderate
influenza and provide an estimated US$102 billion in
annual savings for the US healthcare system. A primary
benefit to society of using OTC medicines to manage
influenza is decreased use of the healthcare system, thereby
mitigating the socioeconomic burden of influenza. Con-
sidering the stresses placed on the US healthcare system
and the substantial productivity losses resulting from
seasonal influenza as well as the growing self-care move-
ment, OTC medicines will play an important role in the
course of future influenza epidemics.
Key Points
As of February 2013, overall vaccine effectiveness
for the 2012/2013 season was estimated to be 56 %.
Vaccination of patients at high risk of influenza-
related complications has been shown to favorably
impact morbidity and mortality. Experts agree that
vaccination benefits healthy adults, but there is still
no consensus on whether the benefit justifies the cost.
Controversy exists regarding the clinical efficacy and
cost effectiveness of antiviral medications, both of
which in the USA are neuraminidase inhibitors.
Inappropriate prescribing of antibacterials for
patients with influenza costs more than
US$200 million annually.
Over-the-counter (OTC) medicines provide
US$102 billion in annual savings, and nearly one-
third of that amount results from consumers self-
treating cough/cold and influenza symptoms.
The use of OTC medicines is one aspect of a
growing movement toward medical self-care and has
become a tool to help individuals manage symptoms
of mild to moderate illnesses and reduce the
healthcare burden on the public budget.
It should be considered that OTC medicines may
play an increasingly important role in mitigating the
socioeconomic burden of influenza.
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Influenza places a significant socioeconomic burden on
individuals, families, and society [1–4]. This burden results
from various direct costs (outpatient and inpatient medical
care plus medications) and indirect costs (productivity
losses) [2]. There are three types of influenza viruses:
Type A viruses tend to have a greater effect on adults,
while Type B viruses are a greater problem in children [5],
but both viruses cause seasonal influenza [6]; Type C is
relatively uncommon [7] and causes only mild illness [6].
Public health experts are most concerned with Type A
influenza virus because new, virulent strains of Type A are
usually the cause of pandemics [6]. Type A strains are
subdivided into groups based on two surface proteins:
hemagglutinin (H) and neuraminidase (N). Because
Type A viruses can be found in humans and animals,
constant animal surveillance is critical to detecting the
emergence of novel viruses with pandemic potential in
humans [6].
Although over-the-counter (OTC; i.e., non-prescrip-
tion) medicines do not directly affect the course of
influenza virus infection or reduce contagion, they may
relieve some influenza-related symptoms, such as fever,
headaches, and body aches [8]. Since influenza is often
self-limiting, many people with mild to moderate influ-
enza can self treat with OTC medicines, rest, and intake
of extra fluids without accessing the healthcare system
[9]. Considering the stresses placed on the US healthcare
system [10] and the substantial productivity losses
resulting from seasonal influenza [3, 7], as well as the
growing self-care movement [11, 12], OTC medicines
will play an important role in the course of future
influenza epidemics. Among less severely ill patients, use
of OTC medicines helps preserve economic productivity
by reducing time absent from work [13]. However,
patients who self medicate and continue working may
infect co-workers.
Individuals who are at risk for influenza-related com-
plications (see Sect. 2.1) should not use OTC medicines to
delay seeking medical attention but should immediately
consult their physician. Many pharmacies are exploring the
use of rapid diagnostic tests and patient assessment tech-
niques to identify patients with influenza at high risk for
complications. This strategy may allow more efficient use
of healthcare resources.
This article explores the socioeconomic impact of
seasonal influenza in the USA and the possible role of
OTC medicines, pharmacists, and the self-care move-
ment in mitigating that impact. The focus is on adult
patients.
2 Overview of Influenza in the USA
2.1 Groups Affected by Influenza
Influenza is an acute, highly contagious viral infection that
causes annual epidemics. The spectrum of disease ranges
from mild to moderate in the majority of the population,
with severe illness and death occurring in high-risk popu-
lations. Influenza viruses can cause disease in any age
group, but rates of serious illness and death are highest
among those aged C65 years [14]. Although the elderly
have immune memory, aging can reduce an individual’s
immune response against an influenza infection [4].
Among older subjects, those with certain underlying
medical conditions are at substantially greater risk for
hospitalization and complications during the influenza
season than healthy adults of the same age [4].
Those at highest risk for influenza-related complications
include children\2 years old; adults C65 years old; those
with weakened immune systems; people of any age with
certain medical conditions such as heart, kidney, liver,
blood, or metabolic diseases [7]; and those with chronic
lung disease (i.e., asthma, chronic obstructive pulmonary
disease, bronchiectasis, or cystic fibrosis) [15]. Among
healthy younger adults, seasonal influenza is typically not
severe and requires hospitalization far less frequently than
in vulnerable groups [4].
Family size is an important variable in determining the
chance of infection because each member interacts with
different groups and then returns to the family, increasing
the risk of infection spread. Single individuals are the least
likely to become infected [16].
2.2 Prevalence, Timing, and Geographic Factors
In the Northern Hemisphere, the influenza season gener-
ally runs from November to May. Timing of influenza
activity is unpredictable, but in the USA the virus most
commonly peaks in January or February [5, 17]. Earlier
seasons are likely to result in more cases of influenza on
both the regional and the national level, as well as higher
morbidity and mortality [14]. Depending on virulence,
vaccination rates, and ability of the year’s influenza
vaccine to match the circulating strains, 15 million to
61 million Americans contract influenza each year [15],
or 5–20 % of the population [5]. Incidence varies greatly
from year to year [4].
An analysis of disease burden performed to estimate the
average annual impact of seasonal influenza was based on
2003 US population demographics and employed surveil-
lance studies, published literature, and data from the
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National Center for Health Statistics, National Hospital
Discharge Survey: 1980–2001, US Census, and National
Health Interview Survey, 2002 (Table 1) [2]. Results
indicated annual occurrence of about 24.7 million cases of
influenza (consistent with other studies [18]), approxi-
mately 31.4 million outpatient visits attributed to influenza
[95 % confidence interval (CI) 22.6–43.5], and 334,185
influenza-related hospitalizations. The majority of hospi-
talizations and deaths occurred in individuals [65 years
old [2]. A Centers for Disease Control and Prevention
(CDC) study published in the Journal of the American
Medical Association in September 2004 and based on data
from 1979 to 2001, found that, on average, [200,000
people in the USA are hospitalized for seasonal influenza-
related complications each year (range 158,000–431,000;
estimate still used today), and there is an overall upward
trend [19]. According to the American Lung Association,
influenza–pneumonia was the sixth leading cause of death
in people [65 years old in 2005 [5].
In a study examining national trends of influenza sea-
sonality, data on hospitalization rates of influenza among
older adults were abstracted from the Centers for Medicare
& Medicaid Services for 1991–2004 [14]. The records of
248,889 influenza patients were analyzed. Across the 13
seasons, the period of highest incidence was consistently
late December to early January. The peak intensity during
this timeframe varied substantially, from 358 cases in the
2002/2003 season to 7,148 cases in the 1999/2000 season
[14]. In terms of peak timing, Nevada, Utah, and California
were the first states to experience influenza; on average,
Rhode Island, New Hampshire, and Maine were the last. A
west-to-east movement of influenza epidemics does appear
to occur [14].
2.3 Symptoms and Diagnosis
Although viral culture may be considered the gold standard
for diagnosing influenza, it is rarely performed clinically
because speed of diagnosis is critical for making treatment
decisions. Instead, the diagnosis is typically based on the
patient’s symptoms (Table 2) and findings of a physical
examination, especially during periods of peak influenza
activity in the community [5, 20]. Influenza is associated
with a variety of symptoms, including fever and cough/sore
throat, and classic definitions vary [21–23].
Interestingly, a retrospective study of 207 inpatients
with a laboratory-confirmed diagnosis of influenza found
that only 60 % had fever and only 51 % had cough or sore
throat [24]. Identification of a patient with influenza-like
illness (ILI) when influenza activity is high (thus improv-
ing positive predictive value) can be used to diagnose
influenza. ILI is defined as fever plus cough and/or sore
throat absent a known cause other than influenza [22].
Additional evidence supporting a diagnosis of influenza
can be gathered with a rapid influenza diagnostic test
(RIDT), which is simple to perform and delivers results in
B15 min. An RIDT can help with treatment decisions, such
as whether to prescribe antiviral medications, by distin-
guishing respiratory illness caused by influenza from ill-
ness caused by other respiratory pathogens [20, 28].
Specificity is high (90–95 %); a positive test result
obtained when influenza is present in the community can
expedite the decision to treat. Similarly, during an outbreak
of respiratory illness, testing can help quickly determine
whether influenza viruses are the cause [29]. If they are,
positive RIDT results can support decisions to promptly
implement prevention and control measures [20]. However,
because sensitivity is low to moderate (40–70 %) and
false-negative results are common, a negative test result
cannot be used to rule out influenza; thus, follow-up is
essential. Also, the test appears to be better at detecting
influenza in children than in adults [29].
Cost efficacy of RIDT in the clinical setting depends on
the probability that the patient has influenza and the drug to
be used for treatment. Generally speaking, when influenza
is probable, empiric treatment is the best strategy regard-
less of the drug used [30–32]. In a recent study, clinical
judgment emerged as the most cost-effective strategy for
adults when influenza comprised 30 % of seasonal ILI
cases. Second was reverse transcriptase–polymerase chain
reaction (RT-PCR); third was point-of-care (rapid) testing
[33]. According to the CDC, however, RT-PCR is not
available for most outpatients and emergency department
patients, and results are not timely enough to inform clin-
ical decision making [34]. Molecular testing is most
appropriate for hospitalized patients if a positive test would
change clinical management and is particularly useful to
Table 1 Influenza-attributable cases leading to outpatient visits,
hospitalizations, and mortality in non–high-risk patients in the USA:
population-based estimates by age groupa







Ill but not medically
attendedb
5,191,816 1,375,732 520,756
Outpatients only 2,374,753 644,607 988,035
Hospitalized patients 31,836 39,711 67,070
Deaths 684 2,660 17,754
Data from Molinari et al. [2]
a The authors combined health outcome rates with US census pop-
ulation estimates by age group in 2003 to estimate the number of
influenza cases in a year by final health outcome
b Individuals with clinical influenza infection who did not seek
medical attention
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identify influenza virus as a cause of respiratory outbreaks
in institutions [34]. Of great interest is cost efficacy of
RIDT in the pharmacy setting. A study of pharmacist-
provided treatment for adult pharyngitis found that phar-
macist use of the rapid antigen detection test (RADT) and
provision of antibacterials depending on results was more
cost effective than the same care by a physician [35]. This
model in all probability would hold for influenza. Under a
collaborative practice agreement with a partnering physi-
cian, a pharmacist could initiate antimicrobial therapy
based on RIDT results within minutes of patient presen-
tation and refer other patients to a provider if warranted.
Pharmacists trained and certified to perform RIDTs and
provide follow-up care can manage the pharmacotherapy
for straightforward, uncomplicated patients, allowing di-
agnosticians to manage more complex patients.
According to the Infectious Diseases Society of America
(IDSA), during influenza season the diagnosis of influenza
should be considered regardless of vaccination status in a
variety of scenarios, including fever and acute onset of
respiratory signs and symptoms in adults and children;
fever and no other signs or symptoms in infants and young
children; and new or worsening respiratory symptoms,
including exacerbation of congestive heart failure or
altered mental status, with or without fever in elderly
patients [36].
Symptoms of influenza start 1–4 days after the virus
enters the body. Adults can transmit the virus 1 day before
symptoms develop and up to 7 days after becoming sick
[37]. Children can transmit the virus for longer than 7 days.
Influenza is primarily transmitted by respiratory droplets
from coughing, sneezing, or talking. It may also be trans-
mitted by fomites [37].
Influenza is one of many acute respiratory infections
(ARIs), a disease group that includes respiratory syncytial
virus (RSV) and pneumonia [38]. ARIs are extremely
common, and influenza is the most serious viral ARI. It is
difficult to distinguish symptoms of influenza from other
viral ARIs [39]. Differentiating influenza virus from the
highly contagious RSV, which also causes epidemics and
can severely affect the same age groups as well as those
with weakened immune systems, is especially important
[40, 41]. Clinical characteristics are rarely distinctive
enough, and laboratory tests to detect RSV in respiratory
secretions of the patient are necessary [41].
Clinicians should contact their local or state health
department for information about current influenza activity.
National information is available online from the CDC’s
Flu Activity & Surveillance page at http://www.cdc.gov/
flu/weekly/fluactivitysurv.htm [20].
2.4 Influenza-Associated Morbidity and Mortality
Although morbidity and mortality associated with influ-
enza have declined among most age groups since 1980,
hospitalizations have increased for those aged C65 years
[14]. This increase has been attributed to the aging of the
US population and the increased prevalence of chronic
medical conditions [42]. During the 1990/1991 through to
1998/1999 influenza seasons, 90 % of influenza–pneumo-
nia deaths occurred in individuals aged C65 years [43].
The number of annual influenza-associated deaths with
Table 2 Defining influenza
Influenza symptoms Illnesses that mimic influenza
• Patient knows exact day that flu hit [25]; symptoms start abruptly,
1–2 days after contagion [4]
• Patient has headache, chills, dry cough, myalgia, exhaustion [25];
eye redness [4]
• Fever is a frequent early symptom [4]
• Illness lasts longer than a cold [25]
• Children may experience nausea, vomiting [25]; gastrointestinal
symptoms (e.g., diarrhea) are common [4]
• Life-threatening complications (e.g., pneumonia) are possible,
especially in frail, young, elderly, or chronically sick individuals [4,
15]
• Illness is very severe in immunosuppressed individuals [4]
Colds: gradual arrival; runny nose, sneezing; fever absent or mild (fever
is a negative predictor of rhinovirus infection in adults) [26]
Streptococcal pharyngitis: sore throat with nasal symptoms typical of
viral pharyngitis, tender unilateral adenopathy and exudate typical of
streptococcal pharyngitis (severe sore throat is evidence against
influenza) [26]
Acute mononucleosis: elevated liver function test results, splenomegaly,
atypical lymphocytes on peripheral smear, positive monospot test [26]
Bacterial pneumonia: pleuritic chest pain, productive sputum (illness
may be concurrent with viral pneumonia or may occur B2 weeks after
recovery from influenza) [26]
Asthma exacerbations, chronic bronchitis, congestive heart failure [27]
Bacterial meningitis: clouded sensorium, prominent headache (early
presentation may be confused with influenza. Influenza should show
improvement within 48 h; it is associated with increased risk of
invasive meningococcal disease) [26]
Encephalitis: fever, change in mental status, stiff neck, headache [26]
Other diseases [many relatively rare conditions can present with
influenza-like symptoms (e.g., inhalational anthrax)] [26]
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underlying respiratory and circulatory causes1 from 1976 to
2007 was 16,612 during the 1976/1977 influenza season
and 15,573 during 2006/2007. The range was 3,349 during
the 1986/1987 season to 48,614 during 2003/2004 [44]. For
these underlying causes, the average annual rate of influ-
enza-associated death was 9.0 deaths per 100,000 persons
(range 1.4–16.7) [44].
3 Impact of Seasonal Influenza in the USA/Economic
Burden
Seasonal influenza can sweep through schools, nursing
homes, workplaces, and towns, resulting in high levels of
worker absenteeism and productivity losses [7]. Clinics and
hospitals can be overwhelmed when large numbers of sick
people present for treatment during peak illness periods [7].
The economic impact on society results primarily from lost
work time and reduced productivity for patients and care-
givers (indirect costs) and increased use of medical
resources (e.g., healthcare professionals’ time, prescribed
medications, laboratory investigations, hospitalizations)
required to treat patients (direct costs) [3]. Typically,
indirect costs account for a greater proportion ([80 %) of
the total societal cost of seasonal influenza epidemics [3].
According to the most current published data on this
topic, in 2003 the total economic burden of influenza epi-
demics in the USA across all age groups was
US$87.1 billion (95 % CI 47.2–149.5; Table 3) [2]. Indi-
rect costs were about US$76.7 billion (88 %) [2]. The
annual burden per capita ranged from US$92 (considering
only lost earnings) to US$299 (including lost lives) [2].
The US healthcare system bears a significant portion of
the economic burden. From 2004 to 2008, influenza was
identified as the fastest-growing disease state in terms of
healthcare spending by employers [10]. Based on 2003
population demographics and prices, direct costs of medi-
cal treatment for influenza amounted to US$10.4 billion
annually, or 12 % of the total economic burden [2].
It has been estimated that influenza results in 0.6–2.5
lost workdays per patient [4], which means, based on an
estimated 24.7 million cases in 2003 [2], that 14.8 million
to 61.7 million workdays may be lost to influenza per year.
The high morbidity and mortality associated with influenza
result in substantial productivity losses [10], amounting to
about US$16.3 billion annually in 2003 (US$6.2 billion
due to morbidity only) [2]. Many adults find that their work
performance is still impaired after returning to work: self
assessments have estimated a maximum effectiveness of
46 % [3]. Caregivers miss work while tending to sick
children and elderly parents. Interestingly, 89 % of con-
sumers believe that OTC medicines are an important part
of their overall family healthcare [45].
4 Prevention of Seasonal Influenza
Influenza vaccination is the primary tool to prevent influ-
enza [36]. Because influenza viruses mutate constantly, the
vaccine has to be modified every year based on a prediction
of which strains will be most predominant [5]. In the USA,
annual vaccination against seasonal influenza is recom-
mended for individuals aged C6 months [46]. In older
people and those with chronic illnesses, vaccination may
1 Per the CDC, if only one category is used to summarize the
mortality effects of influenza, the respiratory and circulatory data
likely provide the most accurate estimates.
Table 3 US total economic burdena of influenza in 2003 by age group and health outcome
Portion of total burden Share of direct medical costsb
Age group
C65 years 64 % (US$55.7 billion) 40 % (US$4.2 billion)
50–64 years 21 % (US$18.3 billion) 27 % (US$2.8 billion)
18–49 years 10 % (US$8.7 billion) 18 % (US$1.9 billion)
\18 years 5 % (US$4.3 billion) 15 % (US$1.7 billion)
Health outcome
Deaths 83 % (US$72.2 billion) 18 % (US$1.9 billion)
Outpatient care 8 % (US$6.8 billion) 30 % (US$3.1 billion)
Hospitalizations 7 % (US$6.0 billion) 52 % (US$5.4 billion)
No medical attention 2 % (US$2.0 billion) \1 % (\US$0.1 billion)
a Total economic burden = direct medical costs, lost earnings from illness, and the value of statistical life (VSL) method of valuation
[medical ? lost earnings ? lost life]
b To treat the disease and its complications; total US$10.4 billion annually
Data from Molinari et al. [2]
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not necessarily prevent influenza, but it can reduce the
symptoms and risk of complications if these individuals do
get sick [25]. Older people are also advised to receive the
pneumococcal vaccine because pneumonia is a major
complication of influenza [5].
4.1 Current Vaccines
There were 13 influenza vaccines available for the
2013/2014 influenza season: nine trivalent and four quad-
rivalent [47]. Each year’s trivalent2 intramuscular vaccine
contains 15 lg of viral antigens from each of two A strains
and one B strain [48] and is specifically formulated to
protect against the three influenza strains that research
suggests will be the most common during the upcoming
season [49, 50]. An intradermal formulation (Fluzone
Intradermal; Sanofi Pasteur) first became available in the
2011/2012 influenza season for use in adults aged
18–64 years [49]. This vaccine contains 9 lg of viral
antigens from each strain; however, intradermal adminis-
tration elicits a stronger immune response [48].
Fluzone and Fluzone High-Dose contain the same
inactivated strains; however, the high-dose formulation
contains 60 lg of viral antigens from each strain and is
designed specifically for people C65 years old [51]. An
ongoing study designed to determine the effectiveness of
Fluzone High-Dose compared with Fluzone is expected
to be completed in 2014/2015. Other trivalent intramus-
cular vaccines include Fluvirin (Novartis) for individuals
C4 years old, Fluarix (GlaxoSmithKline) for those
C3 years old, FluLaval (ID Biomedical Corporation of
Quebec) for those C18 years old, and Afluria (CSL
Biotherapies) for those C9 years old [46].
All but one of the nine current vaccines are inactivated.
FluMist (MedImmune) is the only live, attenuated influ-
enza vaccine (LAIV) and is administered intranasally to
healthy, non-pregnant individuals aged 2–49 years [15,
48]. A new quadrivalent formulation of FluMist for the
same age group is available for the 2013/2014 influenza
season and has replaced the trivalent formulation [47, 50].
Quadrivalent influenza vaccines contain the same three
antigens as trivalent vaccines, along with an antigen from a
second influenza B vaccine virus strain [46]. Other quad-
rivalent vaccines (all inactivated) available for the
2013/2014 season are Fluarix Quadrivalent (Glaxo-
SmithKline), Fluzone Quadrivalent (Sanofi Pasteur), and
FluLaval Quadrivalent (ID Biomedical Corporation of
Quebec) [47, 52, 53].
Flucelvax (inactivated trivalent; Novartis) and Flu-
blok (recombinant trivalent; Protein Sciences) are two
new influenza vaccines that are manufactured using cell
culture technology [54]. Cell-based influenza vaccines are
made by growing viruses in animal or insect cells, instead
of the traditional egg-based process. A major advantage of
cell culture technology is the potential for faster start-up of
the vaccine manufacturing process in the event of a pan-
demic [55]. This formulation is also advantageous for use
in individuals with an egg allergy [55].
4.2 Vaccine Efficacy
As of February 2013, overall vaccine effectiveness for the
2012/2013 season was estimated to be 56 % (95 % CI
47–63) [45]. This efficacy rate was considered ‘‘moderate
efficacy for most people’’ [17]. Against influenza Type A
(H3N2) the efficacy rate was 47 %—only 9 % in individ-
uals aged C65 years—and against Type B it was 67 %
[56]. Subtype H3N2 was the main virus spreading, and
there were not enough H1N1 viruses to estimate the effi-
cacy rate against that subtype [17]. The CDC’s National
Center for Immunization and Respiratory Diseases con-
cluded that more effective vaccines and vaccination strat-
egies are needed [56].
There are fewer data on vaccine efficacy in elderly and
high-risk patients. A 2006 Cochrane review of five ran-
domized trials including [5,000 patients demonstrated a
rate of vaccine effectiveness of 58 % against influenza and
43 % against ILI in these populations [57, 58]. A 2010
Cochrane review of 50 study reports (40 of which included
[70,000 subjects) found that vaccination had a modest
effect on workdays lost and reduction in influenza symp-
toms but had almost no effect on rates of hospital admis-
sions or complications. There is no evidence that
vaccination affects complications (e.g., pneumonia) or
virus transmission [59].
One study found that vaccinated individuals C65 years
old had a 27 % reduction in the risk of hospitalization for
pneumonia or influenza and a 48 % reduction in the risk of
death [5]. These reductions occurred despite the fact that
the individuals also tended to have more serious medical
conditions that should have increased their risk of hospi-
talization or death.
The protection afforded by vaccination is greatly
reduced or absent in some seasons [60]. This conclusion
was based on efficacy data derived from an analysis of 31
studies [17 randomized controlled trials (RCTs) and 14
observational studies] that met strict criteria for design and
conduct. Efficacy of trivalent vaccines in adults
18–64 years old was shown in 8 of 12 seasons (pooled rate
2 Nomenclature alterations for the 2013/2014 season: the term
trivalent influenza vaccine, previously used for inactivated influenza
vaccine, is being replaced with inactivated influenza vaccine (IIV).
IIVs as a class will include egg-based and cell culture-based trivalent
inactivated influenza vaccine (IIV3) and egg-based quadrivalent
inactivated influenza vaccine (IIV4). To refer specifically to cell
culture-based vaccine, the prefix ‘‘cc’’ (e.g., ccIIV3) will be used [47].
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of 59 %) in ten RCTs. Evidence for protection in indi-
viduals 2–17 years old was inconsistent and was lacking in
those C65 years old. Efficacy of LAIVs in children
6 months to 7 years old was shown in 9 of 12 seasons
(pooled rate of 83 %) in ten RCTs. Evidence for protection
in individuals C60 years old was inconsistent and was
lacking in those aged 8–59 years [60].
4.3 Vaccination Rates
In March 2010, RAND conducted a survey of [4,000 US
adults and found that only 39 % underwent influenza
vaccination during the 2009/2010 season. Among adults
specifically recommended for vaccination, rates were only
slightly higher—45 % overall. Reasons for these low sea-
sonal influenza vaccination rates include public resistance
to vaccination and missed opportunities, i.e., visits to a
healthcare provider during flu season when vaccinations
could have been delivered but were not [61]. Additionally,
racial and ethnic disparities exist. Early season data for the
2013–2014 season show a 7.8 % increase in coverage
among Hispanics, making the vaccination rate similar to
that for non-Hispanic whites. However, disparities in vac-
cination remain among non-Hispanic blacks [62].
Influenza vaccination rates for healthcare workers have
remained low for more than three decades, adversely
affecting patient safety [63]. The IDSA suggests that the
USA should require all healthcare workers to undergo
annual influenza vaccination to lower the costs of provid-
ing care and the rates of patient morbidity and mortality
[6].
4.4 Cost Effectiveness and Cost Savings
of Vaccination
Multiple studies in the USA, Canada, UK, and France have
found vaccination to be cost effective and often cost saving
in the elderly and in healthy adults, but other studies offer
an opposing viewpoint regarding vaccination in healthy
adults [64]. A critical factor in determining cost effec-
tiveness and cost savings is vaccine efficacy, which fluc-
tuates from year to year. Many other variables integral to
studying this topic (e.g., influenza rate, number and timing
of physician visits, geographic area) make a true cost–
benefit analysis difficult. To determine the cost effective-
ness of influenza vaccination, antiviral therapy, or no
intervention in healthy working adults, one study of WHO
surveillance data from 1993 to 2002 employed a Markov
model and a number of intensive analyses in an attempt to
address these issues [65]. Results showed that for every
influenza season, except 1997/1998, annual vaccination
was the most cost-effective strategy, and in four of ten
seasons, it was also the least expensive strategy. In half the
years, vaccination was less expensive than no intervention,
which was always the least effective strategy. The authors
stated: ‘‘After 20 years of data collection and public-health
policy analysis, experts agree that vaccination benefits
healthy adults, but there is still no consensus on whether
the benefit justifies the cost’’. Therefore, the answer may be
that vaccination cannot be considered cost effective under
all circumstances [65].
Supportive of this position is a review of seven cost-
effectiveness analyses (three RCTs and four simulation
models) conducted in the USA among healthy adults
18–49 years old and published from 1990 to 2010 [66].
Results suggested that vaccinating the healthy, working-
age population against influenza is generally not cost sav-
ing ‘‘but may be economically attractive under certain
conditions, such as higher illness rates, lower costs of
vaccination, and higher wage rates’’ [66].
4.5 Antiviral Chemoprophylaxis
Prescription antiviral medications can be used to prevent
influenza (approximately 70–90 % effective) [67]. These
medications are useful adjuncts to vaccination, but wide-
spread or routine use of antiviral therapy for chemopro-
phylaxis is not recommended because it may promote
antiviral resistance [67]. Additionally, antiviral therapy
must be administered for the duration of potential exposure
and continued for 7 days following exposure, and adverse
events (AEs) associated with long-term use are uncertain
[68]. Use of preventive antiviral therapy is recommended
for people at high risk for influenza complications who
have been exposed, those with severe immunodeficiencies,
and those who are residents of an institution during an
influenza outbreak in the institution [67]. See Sect. 4.4 for
information on cost efficacy.
5 Treatment of Seasonal Influenza
5.1 Antiviral Drugs
Two US Food and Drug Administration (FDA)-approved
antiviral medications for influenza were recommended for
use in the USA during the 2012/2013 influenza season:
oseltamivir (Tamiflu; Gilead Sciences and F. Hoffmann-
La Roche) and zanamivir (Relenza; GlaxoSmithKline)
[67]. Both are neuraminidase inhibitors (NIs) active against
the influenza A and B viruses and are typically adminis-
tered for 5 days [68]. Oseltamivir is available in pill or
liquid form and is indicated for patients C2 weeks old.
Zanamivir is an inhaled powder indicated for patients
C7 years old [15, 67]. Zanamivir is licensed only for use in
patients without underlying pulmonary or cardiac disease
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[69]. Antiviral therapy can help decrease symptom sever-
ity, shorten disease duration by 1 or 2 days, reduce the risk
of complications and death, and shorten hospitalization
time [15, 67]. The benefit is greatest when treatment is
started as soon as possible after illness onset [68]. Treat-
ment should be started within 48 h of the occurrence of
symptoms and is most effective when begun within 6 h
[57]. However, if a patient with confirmed or suspected
influenza requires hospitalization or has progressive,
severe, or complicated illness, then treatment is recom-
mended even if[48 h have passed since illness onset [68].
5.2 Clinical Efficacy and Cost Effectiveness
of Antiviral Drugs
Controversy exists regarding the clinical efficacy and cost
effectiveness of NIs [70]. Michiels et al. [70] examined
nine systematic reviews and found[50 % efficacy of each
NI for seasonal prophylaxis in healthy adults and individ-
uals at risk for complications, as well as for post-exposure
prophylaxis in healthy adults. Treatment benefit was
\1 day in alleviation of symptoms. The authors concluded
that ‘‘diagnostic uncertainty, risk for virus strain resistance,
side effects, and financial cost outweighs the small bene-
fits’’ of prophylaxis or treatment of ILI in healthy adults.
Prophylaxis of at-risk and elderly groups may be consid-
ered in individual cases, but there is no evidence support-
ing NI treatment in these groups. A systematic review of 22
studies found that use of NIs appeared to be consistently
more cost effective in at-risk and elderly populations [71].
Like Michiels et al., these authors noted marked variations
across studies in approaches, settings, populations, and
assumptions, which led to important differences in the cost-
effectiveness estimates [71]. Of note, a 2014 Cochrane
review of 46 RCTs testing the effects of NIs for prophy-
laxis, post-exposure prophylaxis, and treatment of influ-
enza found treatment benefit of only half a day; no
evidence that either medication reduces the risk of com-
plications, hospitalization, or death, even in patients at high
risk; and minimal effect on prevention [72].
5.3 Inappropriate Antibacterial Use
Unnecessary antibacterial use for influenza continues,
contributing to the ongoing public health problem of anti-
bacterial drug resistance [10]. In fact, millions of antibac-
terials are prescribed by physicians for viral infections each
year [73]. A nationwide US survey of ambulatory care
visits from 1997 to 2001 showed that 38 % of[6.5 million
visits (primary practice, outpatient, and emergency room)
by individuals aged 5–49 years with a sole diagnosis of
influenza were associated with an antibacterial prescription
[74].
A study that assessed the frequency of inappropriate
prescribing of oral antibacterials among 270,057 influenza
patients found that 58,477 (22 %) had received antibacte-
rial prescriptions. Of these, 46,316 antibacterial users had
neither a secondary infection during the ensuing 15-day
period nor a relevant co-morbidity, suggesting that
approximately 79 % of antibacterial use was inappropriate
[10]. Furthermore, the mean cost of an antibacterial pre-
scription was US$40.09. Extrapolated to the entire US
population, inappropriate prescribing of antibacterials for
patients with influenza costs more than US$200 million
annually [10].
5.4 Over-the-Counter (OTC) Medicines
Use of OTC medicines can minimize the discomfort
associated with influenza symptoms, although these drugs
do not treat the infecting virus [5]. OTC medicines are
determined by the FDA to be safe and effective in
addressing label-specified symptoms via a process that
includes review of active ingredients within a therapeutic
class and subsequent development of an OTC Drug
Monograph. The monograph defines the safety and effec-
tiveness of all OTC active ingredients [75].
Of note, 93 % of US adults prefer to treat minor ail-
ments with OTC medicines before seeking professional
care [45]. According to an analysis by the Consumer
Healthcare Products Association (CHPA), OTC medicines
provide US$102 billion in annual savings [45]:
• US$77 billion in clinical cost savings (avoided doctor’s
office visits and diagnostic testing); and
• US$25 billion in drug cost savings (lower priced OTCs
versus higher priced prescription medicines).3
Nearly one-third of that amount results from consumers
self-treating cough/cold and influenza symptoms [45] (see
Sect. 6.1 for additional study details).
6 Use of OTC Medicines in the USA
Approximately 35 % of US adults use OTC medicines on a
regular basis, and there is a trend for increasing use as more
medications move from prescription to OTC status [11]. In
3 CHPA references: ‘‘Overall industry sales and volume data as well
as frequency of purchase data for OTC medicines were sourced from
Symphony IRI, a leading aggregator of consumer health products
industry sales data. List prices for Rx [prescription] products were
obtained from the 2010 version of the Red Book: Pharmacy’s
Fundamental Reference. Ratios of generic-to-branded Rx sales were
estimated based on the 2011–2012 Healthcare Distribution Manage-
ment Association Factbook and Booz & Company analysis. Broader
literature searches contributed the remaining information’’ [13].
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a 2001 survey commissioned by the National Council on
Patient Information and Education, 598 of 1,011 adults
(59 %) surveyed indicated that they had taken OTC med-
icine in the past 6 months [76]. Among these, 52 %
reported that they had taken it to treat cough, cold, influ-
enza, or sore throat. A survey by the Center for Medicine in
the Public Interest of 1,007 adults showed that 66 % relied
on OTC cough medicines to relieve cough symptoms [77],
which are common with influenza.
More than four of five US adults (82 %) who have
experienced various illnesses that can be treated or relieved
by non-prescription medicines self-medicate for these con-
ditions. The main reasons for self-medicating are familiarity
with how to treat the illness because of past experience
(90 %); desire to save time, travel effort, and money (89 %);
and belief that the illness is not serious enough to require
consulting a doctor (78 %) [78]. There are many additional
benefits to use of OTC medicines (Table 4).
According to Euromonitor International, US consumers
spent US$23 billion on OTC medicines in 2010 [13].
Consumers frequently consult pharmacists about OTC
medicines: according to the American Pharmacists Asso-
ciation’s 2008 Annual OTC Product Survey, pharmacists
give approximately 31 OTC medicine recommendations
per week, and an average of 83 % of individuals purchase
the OTC medicine that their pharmacist recommends [76].
Notably, certain high-risk individuals (described previ-
ously) would benefit from a physician visit and diagnosis
rather than self management of influenza-like symptoms.
An 80-year-old patient with asthma, for example, is espe-
cially vulnerable to complications and hospitalization, and
taking OTC medicines may only delay needed care.
Pharmacists can identify such high-risk patients and facil-
itate referral to a physician or other prescriber. For patients
determined to be at lower risk, pharmacists can conduct
assessments and expeditiously recommend either self
management or referral. This would represent a highly
efficient means to access care.
6.1 Socioeconomic Cost Savings with Use of OTC
Medicines
The CHPA created a hypothetical model in which OTC
medicines were unavailable for seven of the most common
categories of acute and chronic, self-treatable conditions:
allergy, analgesics, antifungals, cough/cold/flu, lower and
upper gastrointestinal, and medicated skin [13]. Among the
data sources was a survey of 3,200 consumers to estimate their
likely behavior in this scenario. Overall results showed that:
• Approximately 75 % of today’s OTC medicine con-
sumers (N = 180 million) would seek medical treat-
ment if OTC medicines were not available in the seven
categories studied, triggering significant costs to the US
healthcare system.
• The availability of OTC medicines is estimated to
provide US$102 billion in annual savings to the US
healthcare system:
*50 % (US$52.7 billion) of total OTC value is
captured by employer-based insurance,
*25 % (US$27.5 billion) by Government programs
(Medicare and Medicaid)
*25 % (US$21.7 billion) by the self-insured and
uninsured populations.
• Drug cost savings are about US$25 billion as a result of
using lower-priced OTC medicines rather than higher-
priced prescription medicines.
• The magnitude of savings is particularly high in the
cough/cold/flu category because of the frequency and
prevalence of these conditions.
7 The Self-Care Movement
OTC medicines play an increasingly vital role in the US
healthcare system [75]. The use of OTC medicines is one
Table 4 Characteristics and benefits of over-the-counter medicines
Characteristics [76]
• Have benefits that outweigh risks
• Have low potential for misuse and abuse
• Can be used for self-diagnosed conditions
• Do not require consultation with a healthcare provider
Benefits to patient [76]
• Offer direct, rapid access (prescription not needed) [11]
• Offer convenience and wide availability: drugstores
(pharmacies), grocery stores, mass merchandisers, etc.
• Offer choice: wide variety of treatment options
• Offer self treatment of common conditions
• Can be kept on hand (e.g., home first-aid kit, travel kit)
Benefits to society
• Decrease use of healthcare system (fewer physician visits, lower
system costs) [11]
• Allow healthcare system to focus limited resources on [76]:




• Provide significantly expanded access to treatment [13]
• Contribute to increased economic productivity because of less
time absent from work [13]
• Reduce ‘‘treatment gap’’ (number of people with a condition
who need treatment but do not get it because of cost,
inconvenience, difficulty getting an appointment with their
physician, etc.) [76]
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aspect of a growing movement toward medical self care
and has become a tool to help individuals gain control over
their health [11]. People already treat and manage many of
their ailments without consulting a physician or pharmacist
[79]. In a CHPA 2001 survey, 59 % of Americans polled
said that they were more likely to treat their own health
conditions than they were a year ago [67]. Furthermore,
73 % would rather treat themselves at home than see a
doctor, and six out of ten said that they would like to do
more of this treatment in the future [80]. Interest in self
care has grown as technological advances have created an
information explosion involving wide-open access and
infinite resources. Also, the number of OTC medicines has
surged, patients increasingly want choices, and new and
innovative ways of managing ailments (e.g., self-monitor-
ing equipment, self-diagnosis tools) have evolved [81].
The free market in which non-prescription medicine
manufacturers, who are highly competitive, set prices
based on supply and demand benefits consumers [12].
Furthermore, self medication is being promoted worldwide
as a tool for reducing the healthcare burden on the public
budget [79]. OTC products, such as cough/cold remedies,
analgesics, and decongestants, are commonly used to treat
influenza [81]. The World Medical Association (WMA)
defines responsible self medication as is the use of a reg-
istered or monographed medicine legally available without
a physician’s prescription, either on an individual’s own
initiative or following advice of a healthcare professional.
The WMA further notes that use of prescription medicines
without a prior medical prescription is not responsible self
medication [82]. Benefits of responsible self medication
include the ability to [83]:
• Help prevent and treat symptoms and ailments that do
not require a doctor;
• Reduce the pressure on medical services when health-
care personnel are insufficient;
• Increase the availability of health care in rural or
remote areas;
• Enable patients to control their own chronic conditions;
• Potentially increase wellness and productivity;
• Allow economic gain for employers; and
• Initiate cost savings to healthcare budgets.
In 2013, the World Self-Medication Industry (WSMI)
reviewed 24 independent, published consumer surveys
(conducted from 1987 through 2006) with specific
emphasis on consumers’ practices and attitudes regarding
self care and self medication [84]. The WSMI found that
approximately 92 % of respondents are satisfied with non-
prescription medicines, many believe that they can be as
effective as prescription medicines, OTC drugs are needed
to treat common health problems, and they are used
appropriately, carefully, and safely by most consumers
[84]. Potential risks include [11, 81]:
• Incorrect self diagnosis, delaying diagnosis and treat-
ment of serious illnesses by a healthcare professional;
• Lack of awareness that interactions can occur with
prescription medicines;
• The perception that OTC drugs are less dangerous than
prescription drugs, which may result in overconsump-
tion or inappropriate use;
• Faulty self-monitoring for AEs related to the
medication;
• Vulnerability, leading to reduced capacity for self
management; and
• Absence of a risk:benefit analysis of the OTC drug.
In May 2012, the FDA began consideration of a model
in which some drugs for chronic conditions, such as asthma
and allergies, would be sold under ‘‘conditions of safe
use’’, a proposed category that would describe prescription
drugs sold as OTC medicines. The model would require
development of new technology (e.g., patient kiosks,
remote diagnostic tools, online questionnaires) to help
diagnose and assess patients’ needs. It would expand the
role of pharmacists and reduce that of physicians [85].
Additionally, the model may improve accessibility of pri-
mary healthcare physicians for patients with more severe
illnesses if those with less severe conditions could be
managed by pharmacists.
8 Conclusion
As concerns about the efficacy of the influenza vaccine
remain and healthcare costs continue to rise, OTC
medicines may play an increasingly important role in
mitigating the socioeconomic burden of this pervasive
seasonal illness. For individuals with mild to moderate
influenza symptoms, OTC medicines allow early, cost-
efficient self treatment and patient control. They also
offer convenience, wide availability, and a range of
treatment choices. Socioeconomically, OTC medicines
can reduce use of the healthcare system and contribute to
increased economic productivity by reducing time absent
from work.
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